title: Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.
abstract: Eight hundred and twelve children, 12 months to 3.5 years of age, were enrolled in two clinical studies to evaluate the safety and immunogenicity of a live, attenuated combination vaccine for measles, mumps, rubella, and varicella (MMRV). Children were enrolled in one of two randomized, multicenter studies, involving administration of (1) MMRV and placebo vs. measles, mumps, and rubella vaccine (M-M-R(II)) and varicella-zoster virus vaccine (VARIVAX), given at separate anatomic sites at the same office visit; or (2) MMRV, DTaP (diphtheria, tetanus, and acellular pertussis vaccine) and OPV (oral polio vaccine) vs. M-M-R(II), DTaP, and OPV, with VARIVAX given 6 weeks later. All vaccine regimens were generally well tolerated. More than 95% of vaccinees seroconverted for measles, mumps, rubella, and varicella, regardless of the vaccine or regimen used. In each study, the level of antibody titer to varicella virus was significantly lower in vaccinees receiving MMRV than in those who received VARIVAX in a separate syringe.
authors.affiliation: Department of Clinical Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: White
authors.forename: D
authors.initials: D
authors.lastname: Stinson
authors.forename: B
authors.initials: B
authors.lastname: Staehle
authors.forename: I
authors.initials: I
authors.lastname: Cho
authors.forename: H
authors.initials: H
authors.lastname: Matthews
authors.forename: A
authors.initials: A
authors.lastname: Ngai
authors.forename: P
authors.initials: P
authors.lastname: Keller
authors.forename: J
authors.initials: J
authors.lastname: Eiden
authors.forename: B
authors.initials: B
authors.lastname: Kuter
mesh_terms: D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D016001:Confidence Intervals; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007109:Immunity; D007114:Immunization / Q000379:methods*; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D008458:Measles Vaccine / Q000008:administration & dosage / Q000276:immunology; D009108:Mumps Vaccine / Q000008:administration & dosage / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000276:immunology; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D017778:Vaccines, Combined / Q000008:administration & dosage* / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D014777:Virus Diseases / Q000517:prevention & control*
chemical_list: D019433:Chickenpox Vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D008458:Measles Vaccine; D009108:Mumps Vaccine; D011055:Poliovirus Vaccine, Oral; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D014765:Viral Vaccines